4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
Medscape1d
Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMD
In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...
EurekAlert!1d
KRISS partners with domestic university hospitals to develop disease diagnosis and treatment technology, alleviating patient burden
The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes -- Positive Topline Results ...
ophthalmologytimes2d
HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA
The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...
modernretina2d
FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics
The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of neovascular AMD. Primary endpoints include the safety and tolerability of ...
ophthalmologytimes6d
Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...